BR9610323A - Novas isoquinolinas fundidas como ligantes de receptor de dopamina - Google Patents

Novas isoquinolinas fundidas como ligantes de receptor de dopamina

Info

Publication number
BR9610323A
BR9610323A BR9610323-0A BR9610323A BR9610323A BR 9610323 A BR9610323 A BR 9610323A BR 9610323 A BR9610323 A BR 9610323A BR 9610323 A BR9610323 A BR 9610323A
Authority
BR
Brazil
Prior art keywords
receptor ligands
dopamine receptor
new fused
isoquinolines
fused isoquinolines
Prior art date
Application number
BR9610323-0A
Other languages
English (en)
Inventor
David E Nichols
Richard Mailman
Debasis Ghosh
Original Assignee
Perdue Research Foundation
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perdue Research Foundation, Univ North Carolina filed Critical Perdue Research Foundation
Publication of BR9610323A publication Critical patent/BR9610323A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"NOVAS ISOQUINOLINAS FUNDIDAS COMO LIGANTES DE RECEPTOR DE DOPAMINA". A presente invenção é dirigida a novos ligantes de receptor de dopamina de fórmula (I), formulações farmacêuticas de tais compostos,e um método de utilização de tais compostos para o tratamento de um paciente sofrendo de disfunção relacionada a dopamina do sistema nervoso central ou periférico.
BR9610323-0A 1995-08-18 1996-08-16 Novas isoquinolinas fundidas como ligantes de receptor de dopamina BR9610323A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US251995P 1995-08-18 1995-08-18
PCT/US1996/013416 WO1997006799A1 (en) 1995-08-18 1996-08-16 Novel fused isoquinolines as dopamine receptor ligands

Publications (1)

Publication Number Publication Date
BR9610323A true BR9610323A (pt) 1999-12-21

Family

ID=21701148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610323-0A BR9610323A (pt) 1995-08-18 1996-08-16 Novas isoquinolinas fundidas como ligantes de receptor de dopamina

Country Status (18)

Country Link
US (2) US5959110A (pt)
EP (1) EP0845988B1 (pt)
JP (1) JP2000505046A (pt)
CN (1) CN1199338A (pt)
AT (1) ATE209915T1 (pt)
AU (1) AU700688B2 (pt)
BR (1) BR9610323A (pt)
CA (1) CA2227585A1 (pt)
DE (1) DE69617700T2 (pt)
DK (1) DK0845988T3 (pt)
ES (1) ES2169257T3 (pt)
IL (1) IL122974A (pt)
MX (1) MX9801179A (pt)
NO (1) NO308658B1 (pt)
NZ (1) NZ316312A (pt)
PT (1) PT845988E (pt)
RU (1) RU2177001C2 (pt)
WO (1) WO1997006799A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ316312A (en) * 1995-08-18 1999-06-29 Purdue Research Foundation Novel fused isoquinolines as dopamine receptor ligands
KR20030027020A (ko) * 2000-08-11 2003-04-03 펄듀 리서치 파운데이션 디나프솔린의 제조 공정
CA2434736A1 (en) * 2001-01-16 2002-07-25 Purdue Research Foundation Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
WO2003013532A1 (en) * 2001-08-10 2003-02-20 Purdue Research Foundation Chiral dinapsoline
EP1480647B1 (en) * 2002-02-15 2008-09-03 Darpharma, INC. Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
JP2004190007A (ja) * 2002-11-27 2004-07-08 Konica Minolta Holdings Inc 色素およびインクジェット記録液
EP1668363A1 (en) * 2003-09-24 2006-06-14 Biacore AB Method and system for molecular interaction analysis
NZ570606A (en) * 2006-02-21 2011-11-25 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
PL2317852T3 (pl) * 2008-07-16 2015-05-29 Richter Gedeon Nyrt Preparaty farmaceutyczne zawierające ligandy receptora dopaminy
JP5734957B2 (ja) 2009-04-21 2015-06-17 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用
CN110068645B (zh) * 2019-04-03 2021-09-03 上海药明奥测医疗科技有限公司 液质联用检测尿液中环磷酸腺苷的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346090A (en) * 1977-07-21 1982-08-24 Ayerst, Mckenna & Harrison Ltd. 13-Chloro-benzocycloheptapyridoisoquinolines and use as neuroleptics
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
IE912999A1 (en) * 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
DE69334206D1 (de) * 1992-05-26 2008-04-03 Purdue Research Foundation Substituierte hexahydrobenzo(a) phenanthridine
NZ316312A (en) * 1995-08-18 1999-06-29 Purdue Research Foundation Novel fused isoquinolines as dopamine receptor ligands

Also Published As

Publication number Publication date
PT845988E (pt) 2002-05-31
ES2169257T3 (es) 2002-07-01
IL122974A0 (en) 1998-08-16
DE69617700T2 (de) 2002-07-18
ATE209915T1 (de) 2001-12-15
MX9801179A (es) 1998-04-30
JP2000505046A (ja) 2000-04-25
NO980688L (no) 1998-02-18
AU6851396A (en) 1997-03-12
CN1199338A (zh) 1998-11-18
NO308658B1 (no) 2000-10-09
CA2227585A1 (en) 1997-02-27
EP0845988A1 (en) 1998-06-10
US5959110A (en) 1999-09-28
WO1997006799A1 (en) 1997-02-27
US6194423B1 (en) 2001-02-27
NO980688D0 (no) 1998-02-18
RU2177001C2 (ru) 2001-12-20
AU700688B2 (en) 1999-01-14
EP0845988B1 (en) 2001-12-05
DK0845988T3 (da) 2002-04-02
NZ316312A (en) 1999-06-29
EP0845988A4 (en) 1998-11-11
DE69617700D1 (de) 2002-01-17
IL122974A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
RO115522B1 (ro) Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament
DE69936998D1 (de) Pyrazolotriazinderivate als gaba-rezeptorliganden
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
BR9610323A (pt) Novas isoquinolinas fundidas como ligantes de receptor de dopamina
BG100830A (en) Naphthylamides as central nervous system agents
TNSN98035A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
ATE247639T1 (de) Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden
DE60232029D1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
PT912184E (pt) Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
DE60003899D1 (de) Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
UA32536C2 (uk) 1r-цис,1'r-цис-2,2'-(3,11-діоксо-4,10-діоксатридецилен)біс-1,2,3,4-тетрагідро-6,7-диметокси-2-метил-1-вератрилізохінолінієва сіль, спосіб її одержання, фармацевтична композиція, спосіб забезпечення нервово-м'язової блокади
BR9803385A (pt) AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas.
HUP9900360A2 (hu) Eljárás norbenzomorfánszármazékok előállítására
DE69736180D1 (de) Behandlung von manischen erkrankungen
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
ATE369354T1 (de) Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems
ATE198984T1 (de) Verwendung von phenoxypyridinderivaten zur behandlung der durch stoerungen des dopaminsystems verursachten erkrankungen

Legal Events

Date Code Title Description
FF Decision: intention to grant
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
HKFF Publication of grant (deleted)
HHFI Decision: rectification
FG9A Patent or certificate of addition granted
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 9A,10A,11A12A,13A,14A E 15A ANUIDADE(S).

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.